哮喘药物的基因组学研究进展  

Advance in Search for Pharmacogenomics of Asthma

作　　者：周斌[1] 刘宏[2] 殷明[1] 

机构地区：[1]上海第二军医大学药学院药理学教研室,上海200433 [2]上海第二军医大学长海医院,上海200433

出　　处：《中国临床药理学杂志》2003年第1期63-66,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：哮喘是一种多因性疾病,遗传因素在其病理机制中发挥重要作用,并使不同病人的疾病表型有极大的不同。某些基因是哮喘发生的易感因素,某些基因是哮喘发生的调节因子,它们会影响哮喘发作的严重程度以及患者对治疗药物的反应性,药物基因组学的目的就是要运用这方面的数据对个体患者进行更有效的治疗。本文综述了哮喘药物基因组学方面的研究进展,β_2肾上腺素受体基因的多态性影响患者对β_2肾上腺素受体激动剂的反应性,5-脂氧合酶和白三烯C_4合成酶基因的多态性也影响对白三烯途径治疗措施的效应,但尚未确定影响抗胆碱疗法效应和参与皮质激素耐受机制的基因多态性。Current knowledge of asthma suggests that, despite its multifactorial etiopathogenesis, genetics plays a primary role in orchestrating the pathological events, and even dramatically changes the disease phenotype from patient to patient. Genes may act as susceptibility factors, increasing the risk of disease development, or may operate as regulatory factors, modulating the magnitude and severity of pathogenic processes and the response to drug treatment. The goal of pharmacogenomics is the application of this knowledge to elaborate more specific and effective treatments and to tailor therapies to individual patients according to their genetic profile. Here we outline the recent progress in the pharmocogenomics of asthma as they pertain to the treatments available. Polymorphisms in the β2-adrenergic receptor gene influence responsiveness to β 2-agonists. Polymorphisms in the 5-lipoxygenase gene and the leukoriene C4 synthase gene have been associated with response to medications that target the leukotriene pathway. However, no polymorphisms have been identified that influence response to anticholinergics or are involved in steroid resistance.

关 键 词：哮喘 药物基因组学 Β2肾上腺素受体激动剂 白三烯调节剂 基因多态性 

分 类 号：R974.3[医药卫生—药品]